19 sources
Who is covering this
FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness
The Food and Drug Administration is adding a new warning about possible rare cases of vision loss reported with GLP-1 drugs like Ozempic, Wegovy and other brands. The Food and Drug Administration is adding a new warning about possible...
NDTV GLP-1 Drugs Receive New Warning Labels Over Rare Blindness Risk
The order applies to all GLP-1s.
Lean: Center Fact-focusedFactuality: HighCountry: IndiaFunding: CorporateOwner: RRPR HoldingCNBC FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Lean: Center Fact-focusedFactuality: HighCountry: United StatesFunding: Corporate
Zero Hedge "Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs
"Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs The FDA is requiring the makers of every GLP-1 drug on the U.S. market, Ozempic, Wegovy, Mounjaro and Zepbound among them, to...
Low reliability sourceElevated riskLean: Right Fact-focusedFactuality: LowCountry: United StatesFunding: PrivateOwner: ABC Media Ltd
CBS News GLP-1s must now include warning for potential increased risk of vision loss, FDA announces
The FDA announced that GLP-1 weight loss drugs will now include warning labels indicating a potential increased risk of vision loss.
Lean: Leans left Fact-focusedFactuality: HighCountry: United StatesFunding: CorporateOwner: Paramount Global



.jpeg?width=1200&auto=webp&crop=3%3A2)







